DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol by Cassandra White, Hannah Wardill, Christine Paul, Timothy Price, Christos Karapetis, Mark Nalder, Matthew E. Burge, Ann Thomas, Chris Oldmeadow, Daniel Barker, Laura C. Edney, Janet Coller, Joanne Bowen, Cheri Ostroff, Bruce Cheek, Mel Carlson, Trumaine Rankmore, Adnan Nagrial, Stephen Clarke, Lorraine Chantrill, Stephen Ackland, Rodney J. Scott

Subjects: Get full text

The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐FU in pancreatic cancer by Hiroyuki Kato, Motonori Sato, Aya Naiki‐Ito, Shingo Inaguma, Makoto Sano, Masayuki Komura, Yuko Nagayasu, Kuang Xiaochen, Akihisa Kato, Yoichi Matsuo, Hideaki Ijichi, Satoru Takahashi

Subjects: Get full text

DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol by Ana Hernández-Guío, M.ª Ángeles Bernabéu-Martínez, Andrés Corno-Caparrós, M.ª Teresa Aznar-Saliente, Manuel Bonete-Sánchez, Miguel Ángel Calleja-Hernández

Subjects: Get full text